Literature DB >> 3409576

Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965-1984.

T J Arneson1, L J Melton, D G Lewallen, W M O'Fallon.   

Abstract

Over the 20-year period from 1965 to 1984, 370 residents of Rochester, Minnesota experienced 402 femoral fractures exclusive of the hip, giving an overall incidence rate of 37.1 per 100,000 person-years (95% confidence interval, 33.4-40.8). Of these, 54 were subtrochanteric and 210 were diaphyseal, while 123 involved the distal femur and 15 were at unspecified femoral sites. Fifty-eight percent of these fractures were caused by severe trauma. The incidence of femoral fractures due to severe trauma was greatest in young patients, especially for diaphyseal fractures, and showed a male excess. One-third of the fractures were associated with moderate trauma and were responsible for the rising incidence rates with age at all three fracture sites. These increases were greater in women. Eighty percent of patients 35 years of age or older with fractures due to moderate trauma had prior evidence of generalized osteopenia or a condition likely to cause localized osteopenia in the fractured femur. These data confirmed similar findings from Sweden, providing evidence for a relationship between osteoporosis and femoral fractures distal to the hip.

Entities:  

Mesh:

Year:  1988        PMID: 3409576

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  34 in total

1.  Aging is not a risk factor for femoral and tibial fractures in motor vehicle crashes.

Authors:  Gabriel Ryb; Patricia Dischinger; Michael Kleinberger; Cynthia Burch; Shiu Ho
Journal:  Ann Adv Automot Med       Date:  2008-10

2.  Internal fixators: a safe option for managing distal femur fractures?

Authors:  Bruno Bellaguarda Batista; Rodrigo Salim; Cleber Antonio Jansen Paccola; Mauricio Kfuri Junior
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

3.  Retrograde femoral nailing in elderly patients with supracondylar fracture femur; is it the answer for a clinical problem?

Authors:  Sameh El-Kawy; Sameh Ansara; Alaa Moftah; Hisham Shalaby; Vinod Varughese
Journal:  Int Orthop       Date:  2006-05-09       Impact factor: 3.075

4.  The impact of subtrochanteric fracture criteria on hip fracture classification.

Authors:  S Y Huang; C D Grimsrud; J Provus; M Hararah; M Chandra; B Ettinger; J C Lo
Journal:  Osteoporos Int       Date:  2011-05-12       Impact factor: 4.507

5.  Use of renal function measurements for assessing fracture risk in postmenopausal women.

Authors:  James T McCarthy; Andrew D Rule; Sara J Achenbach; Eric J Bergstralh; Sundeep Khosla; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2008-11       Impact factor: 7.616

6.  Fracture risk in type 2 diabetes: update of a population-based study.

Authors:  L Joseph Melton; Cynthia L Leibson; Sara J Achenbach; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

7.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

Authors:  B Dawson-Hughes; A N A Tosteson; L J Melton; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 8.  [Fractures of the shaft of the femur].

Authors:  T Lögters; J Windolf; S Flohé
Journal:  Unfallchirurg       Date:  2009-07       Impact factor: 1.000

9.  Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures.

Authors:  Nicola Napoli; Ann V Schwartz; Lisa Palermo; Jenny J Jin; Rosanna Wustrack; Jane A Cauley; Kristine E Ensrud; Michael Kelly; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

10.  Secular trends in hip fracture incidence and recurrence.

Authors:  L J Melton; A E Kearns; E J Atkinson; M E Bolander; S J Achenbach; J M Huddleston; T M Therneau; C L Leibson
Journal:  Osteoporos Int       Date:  2008-09-17       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.